Bioavailability & Solubility

2017 GLOBAL DRUG DELIVERY & FORMULATION REPORT – Notable Technologies, Approvals, Transactions, Pipelines & Perspectives

This third annual report, a collaborative effort between team members at Drug Development & Delivery and PharmaCircle, provides a look back at 2016 in terms of approvals and developments in the area of drug delivery and formulation. The report continues to cover the following significant key points of interest, with the belief that understanding the past, even the recent past, can provide insights to what is possible.

PLATFORM TECHNOLOGY – ​​The 3DNA® Platform for Targeted Drug Delivery

Robert C. Getts, PhD, and Jessica Bowers review how the 3DNA platform is composed entirely of noncoding DNA assembled through the sequential hybridization of single strands of DNA into a network of double-stranded nucleic acid having a controlled architecture, and multiple attachment sites for drug and targeting molecules.

EXCLUSIVE ONLINE CONTENT

7/8/2018

Pfenex Receives Milestone From Merck

Pfenex Inc. recently announced the receipt of a milestone payment from Merck associated with the initiation of the first Phase 3 clinical study of (V114), an investigational polyvalent conjugate vaccine for the prevention of pneumococcal disease. 

7/8/2018

Immatics Enters Strategic Partnership With Genmab

Immatics Biotechnologies GmbH recently announced it has entered into a research collaboration and license agreement with Genmab A/S to develop next-generation, T-cell engaging bispecific immunotherapies targeting multiple cancer indications.

7/8/2018

Gerresheimer Acquires Sensile Medical

With the acquisition of Sensile Medical AG, Switzerland  under a recent share purchase agreement, Gerresheimer is extending its business model in the direction of an Original Equipment Manufacturer (OEM) for drug delivery platforms with digital and electronic capabilities for pharmaceutical and biopharmaceutical customers.